Engineered immune cells take on progressive MS in first human test
NCT ID NCT06138132
First seen Feb 28, 2026 · Last updated Jun 16, 2026 · Updated 13 times
Summary
This early-phase study tests a new treatment called KYV-101 for people with progressive forms of multiple sclerosis (MS) that are not getting better with standard care. The treatment uses a patient's own immune cells, modified to target and destroy certain immune cells that may drive MS. The main goal is to check safety and find the right dose in 12 adults aged 18 to 65.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford Multiple Sclerosis Center
RECRUITINGPalo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.